Latest news articles

Added 24 days ago Drug news

NICE recommends Takhzyro for hereditary angioedema.- Takeda

Takeda announced that the National Institute for Health and Clinical Excellence (NICE) has issued its Final Appraisal Determination recommending Takhzyro...

Added 1 month ago Drug news

ADMA Biologics, Inc. announces the commercial relaunch and its first commercial sales of Bivigam for primary humoral immunodeficiency

ADMA Biologics, Inc. a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures and markets three approved plasma-derived biologics...

Added 3 months ago Drug news

FDA approves Xembify, a 20% subcutaneous immunoglobulin to treat primary immunodeficiencies

Grifols announced that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the FDA. Xembify is used to treat...

Search all news articles for Immunity disorders
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

Load more

Guidelines

ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...

Added 6 years ago

Search all guidelines for Immunity disorders
 

Journal articles

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®)...

Added 1 year ago

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.

Added 2 years ago

Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders

Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...

Added 5 years ago

Search all journal articles for Immunity disorders
 
Lauren McCracken

Lauren McCracken works for our sister agency Digital Medical Communications (DMC Ltd) as an Associate Medical Writer. Lauren is very passionate about healthcare and how technology can improve treatments, and has written a blog series 'Transforming lives through technology'

... Read more

EAACI hot topics: Allergen specific immunotherapy (AIT)

When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.